stock decline

AGL faces securities fraud allegations over false 2025 guidance. Stock plunged 51.5% after guidance suspension; investors have until March 2026 deadline to join class action.

BellRing Brands faces securities lawsuit over allegedly false statements about sales growth. Investors have until March 23 to join the class action suit.

Law firm sues REGENXBIO for allegedly hiding safety concerns about gene therapy RGX-111. Stock dropped 17.8% after FDA clinical hold due to tumor in trial participant.

DraftKings stock fell 13.73% despite beating Q4 earnings, as cautious 2026 guidance projecting just 11% growth spooked investors expecting faster momentum.

KDDI delays Q3 earnings report due to internal investigation, causing ADR stock to plunge 11.4%. Securities firms examine potential investor claims over disclosure accuracy.

Richtech Robotics faces class action lawsuit for allegedly making false claims about Microsoft partnership. Stock fell 20.87% after critical report questioned the deal's validity.

Sanofi CEO Paul Hudson steps down February 17; Belén Garijo takes over post-AGM. Stock fell 4.5% on leadership transition announcement amid vaccine sales decline concerns.

Law firm Kaskela initiates shareholder investigation into Priority Technology over 50% stock decline since February, examining potential securities violations and fiduciary duty breaches.

E.l.f. Beauty and On Holding stocks fell sharply but maintain strong growth—38% and 35% revenue expansion respectively—now trading at potentially attractive valuations amid market pullback.

Rosen Law Firm investigates KDDI for delayed earnings disclosure and potential securities violations. Stock fell 11.4% following announcement of internal investigation.